News coverage about The Joint (NASDAQ:JYNT) has trended somewhat positive this week, according to Accern. The research firm rates the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. The Joint earned a news impact score of 0.16 on Accern’s scale. Accern also assigned media stories about the company an impact score of 46.6064040505361 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

These are some of the news articles that may have effected Accern Sentiment’s scoring:

The Joint (NASDAQ:JYNT) remained flat at $$5.27 during trading hours on Thursday. 14,900 shares of the stock were exchanged, compared to its average volume of 31,577. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.32 and a quick ratio of 1.32. The Joint has a 12-month low of $1.96 and a 12-month high of $6.00.

The Joint (NASDAQ:JYNT) last posted its quarterly earnings data on Thursday, November 9th. The company reported ($0.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.03. The company had revenue of $6.55 million during the quarter, compared to analysts’ expectations of $6.28 million. The Joint had a negative net margin of 36.74% and a negative return on equity of 98.28%. equities research analysts predict that The Joint will post -0.27 earnings per share for the current year.

A number of equities research analysts have recently issued reports on the stock. Maxim Group reiterated a “buy” rating and set a $7.00 price target on shares of The Joint in a research report on Friday, August 11th. Zacks Investment Research raised shares of The Joint from a “hold” rating to a “buy” rating and set a $5.00 price objective for the company in a research note on Wednesday, September 27th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $5.86.

ILLEGAL ACTIVITY NOTICE: This report was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this report can be accessed at

The Joint Company Profile

The Joint Corp. develops, owns, operates, supports and manages chiropractic clinics through direct ownership, management arrangements, franchising and the sale of regional developer rights throughout the United States. The Company is franchisor and operator of chiropractic clinics. The Company offers its patients the opportunity to visit its clinics without an appointment and receive prompt attention.

Insider Buying and Selling by Quarter for The Joint (NASDAQ:JYNT)

Receive News & Stock Ratings for The Joint Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Joint Corp. and related stocks with our FREE daily email newsletter.